Bexorg is a pioneering biotechnology company dedicated to transforming central nervous system (CNS) drug discovery and development. Utilizing its proprietary BrainEx platform, Bexorg restores metabolic and molecular activity in postmortem human brains, enabling the generation of high-fidelity, clinically predictive data. This innovative approach allows for the study of brain connectivity, circuit function, and disease processes in a way previously unattainable, providing unprecedented insights into human neurobiology. Key Features and Functionality: - BrainEx Platform: A cutting-edge whole-brain perfusion technology that maintains isolated human and pig brains in a metabolically active state, facilitating real-time tracking of transcriptomic, proteomic, metabolic, and biomarker responses. - XO Digital Engine: An AI-driven system that learns from each experiment, creating a closed-loop of in-silico prediction and wet-lab validation, thereby enhancing the efficiency and accuracy of CNS drug discovery. - Comprehensive Human Brain Datasets: By generating extensive human brain molecular data, Bexorg trains predictive models across various neurological diseases, leading to the identification of novel targets and biomarkers. Primary Value and User Solutions: Bexorg addresses the high failure rates in CNS drug development by providing a platform that closely mirrors human brain physiology. This approach de-risks the drug development process by enabling preclinical testing of therapeutics in metabolically active whole human brains, offering significant advantages over traditional models. By delivering detailed insights into drug distribution, mechanism of action, target engagement, and CNS biomarker identification, Bexorg empowers pharmaceutical partners to make informed decisions, ultimately accelerating the development of effective therapies for neurological disorders.